Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 1185

1.

Retrovirally transduced bone marrow-derived dendritic cells require CD4+ T cell help to elicit protective and therapeutic antitumor immunity.

De Veerman M, Heirman C, Van Meirvenne S, Devos S, Corthals J, Moser M, Thielemans K.

J Immunol. 1999 Jan 1;162(1):144-51.

3.

Dendritic cells retrovirally transduced with a model antigen gene are therapeutically effective against established pulmonary metastases.

Specht JM, Wang G, Do MT, Lam JS, Royal RE, Reeves ME, Rosenberg SA, Hwu P.

J Exp Med. 1997 Oct 20;186(8):1213-21.

5.
6.

Dendritic cells loaded with exogenous antigen by electroporation can enhance MHC class I-mediated antitumor immunity.

Kim KW, Kim SH, Jang JH, Lee EY, Park SW, Um JH, Lee YJ, Lee CH, Yoon S, Seo SY, Jeong MH, Lee ST, Chung BS, Kang CD.

Cancer Immunol Immunother. 2004 Apr;53(4):315-22. Epub 2003 Dec 18.

PMID:
14685778
7.

Induction of antitumor immunity using bone marrow-generated dendritic cells.

Porgador A, Snyder D, Gilboa E.

J Immunol. 1996 Apr 15;156(8):2918-26.

PMID:
8609412
10.

Immunization with a lentiviral vector stimulates both CD4 and CD8 T cell responses to an ovalbumin transgene.

Rowe HM, Lopes L, Ikeda Y, Bailey R, Barde I, Zenke M, Chain BM, Collins MK.

Mol Ther. 2006 Feb;13(2):310-9. Epub 2005 Nov 4.

11.

The generation of both T killer and Th cell clones specific for the tumor-associated antigen HER2 using retrovirally transduced dendritic cells.

zum B├╝schenfelde CM, Metzger J, Hermann C, Nicklisch N, Peschel C, Bernhard H.

J Immunol. 2001 Aug 1;167(3):1712-9.

12.
15.

Potent vaccine therapy with dendritic cells genetically modified by the gene-silencing-resistant retroviral vector GCDNsap.

Nabekura T, Otsu M, Nagasawa T, Nakauchi H, Onodera M.

Mol Ther. 2006 Feb;13(2):301-9. Epub 2005 Nov 28.

16.

Induction of antitumor immunity with dendritic cells transduced with adenovirus vector-encoding endogenous tumor-associated antigens.

Kaplan JM, Yu Q, Piraino ST, Pennington SE, Shankara S, Woodworth LA, Roberts BL.

J Immunol. 1999 Jul 15;163(2):699-707.

17.

The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.

Ojima T, Iwahashi M, Nakamura M, Matsuda K, Naka T, Nakamori M, Ueda K, Ishida K, Yamaue H.

Int J Oncol. 2006 Apr;28(4):947-53.

PMID:
16525645
18.

Transduction of dendritic cells by antigen-encoding lentiviral vectors permits antigen processing and MHC class I-dependent presentation.

Zarei S, Leuba F, Arrighi JF, Hauser C, Piguet V.

J Allergy Clin Immunol. 2002 Jun;109(6):988-94.

PMID:
12063529
19.

Strategies for antigen choice and priming of dendritic cells influence the polarization and efficacy of antitumor T-cell responses in dendritic cell-based cancer vaccination.

Galea-Lauri J, Wells JW, Darling D, Harrison P, Farzaneh F.

Cancer Immunol Immunother. 2004 Nov;53(11):963-77. Epub 2004 May 14.

PMID:
15146294
20.

Dendritic cells charged with apoptotic tumor cells induce long-lived protective CD4+ and CD8+ T cell immunity against B16 melanoma.

Goldszmid RS, Idoyaga J, Bravo AI, Steinman R, Mordoh J, Wainstok R.

J Immunol. 2003 Dec 1;171(11):5940-7.

Supplemental Content

Support Center